Comparison of cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers

A comparison between cimetidine and tripotassium dicitrato bismuthate liquid (TDB) in the treatment of endoscopically diagnosed duodenal ulcer by single-blind randomized trial in 48 patients has shown 18 (75%) out of 24 patients receiving TDB and 13 (54%) out of 24 patients receiving cimetidine heal...

Full description

Saved in:
Bibliographic Details
Published inDigestion Vol. 28; no. 2; p. 96
Main Authors Shreeve, D R, Klass, H J, Jones, P E
Format Journal Article
LanguageEnglish
Published Switzerland 01.01.1983
Subjects
Adolescent
Adult
Age Factors
Aged
Bismuth - therapeutic use
Cimetidine - therapeutic use
Clinical Trials as Topic
Duodenal Ulcer - diagnosis
Duodenal Ulcer - drug therapy
Duodenal Ulcer - prevention & control
Duodenoscopy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Organometallic Compounds
Random Allocation
Recurrence
Time Factors
Wound Healing - drug effects
Online AccessGet more information

Cover

More Information
Summary:A comparison between cimetidine and tripotassium dicitrato bismuthate liquid (TDB) in the treatment of endoscopically diagnosed duodenal ulcer by single-blind randomized trial in 48 patients has shown 18 (75%) out of 24 patients receiving TDB and 13 (54%) out of 24 patients receiving cimetidine healed after 4 weeks' therapy. Symptomatic improvement within 1 month was seen in 19 patients on TDB and 18 patients on cimetidine, but did not only occur in patients whose ulcers healed. On follow-up, endoscopically proven relapse occurred within 1 year in 47% of patients whose ulcers had healed during treatment with TDB in comparison with 60% of those healing on cimetidine.
ISSN:0012-2823
DOI:10.1159/000198970